Begin main content


We found 4947 result(s)

Biosimilars — Regulatory, Health Technology Assessment, Reimbursement Trends, and Market Outlook

Published on: January 19, 2018
Result type: Reports
Product Line: Environmental Scans

The Environmental Scan identifies and compares information regarding the regulatory frameworks, HTA processes, and reimbursement trends of national and international organizations. It also provides a synopsis of the market outlook for biosimilars and their reference products in Canada. The findings of this Environmental Scan are based on a liter...

  • Project Number: ES0317-000


Biologics, Biosimilar Pharmaceuticals, Government Regulation, Pricing, Reimbursement Mechanisms, Technology Assessment, Therapeutic Equivalency, Other miscellaneous topics, Biomedical, SEB, biosimilar, follow-on, interchangeability, interchangeable, regulatory, subsequent entry, subsequent entry biologic, subsequent entry biopharmaceutical, subsequent entry biopharmaceuticals, subsequent entry biotherapeutic, subsequent entry biotherapeutics

Canadian Medical Imaging Inventory (CMII)

Published on: January 19, 2018
Result type: Reports
Product Line: Optimal Use
Research Type: Device

The Canadian Medical Imaging Inventory (CMII) was created to capture information on the number, location, and use of CT, MRI, PET-CT, single-photon emission tomography (SPECT) and SPECT-CT, and PET-MRI machines across Canada. It is designed to help guide strategic planning and identify gaps in service. The CMII also collects data on the age, loc...

  • Project Number: OP0529-000

dupilumab (Dupixent)

Last Updated: January 18, 2018
Result type: Reports
Product Line: Common Drug Review
Generic Name: dupilumab
Indications: atopic dermatitis

  • Brand Name: Dupixent
  • Manufacturer: Sanofi-Genzyme
  • Project Number: SR0533-000
  • Project Status: Suspended
  • Submission Type: New


Dermatology, Dermatitis, Atopic, Dermatology, dupilumab; dupixent; Dermatitis; eczema